The Human IGF-1 (Insulin-Like Growth Factor 1) ELISA Kit Market is developing across North America, Europe, Asia-Pacific, South America, and the Middle East and Africa. The global market is projected to increase from USD 693.4 million in 2025 to USD 1.2 billion by 2035, reflecting a CAGR of 5.6%.

North America is anticipated to maintain market leadership because of its advanced healthcare infrastructure, strong biotechnology sector, and significant investment in medical research. The region also benefits from the presence of major diagnostic and life-science companies.

Europe is another important market, supported by investments in biotechnology, clinical research, precision medicine, and laboratory diagnostics. Growing adoption of advanced assay technologies is expected to support regional development.

Asia-Pacific is projected to demonstrate significant growth during the forecast period. Increasing healthcare expenditure, expanding pharmaceutical industries, and greater investment in research and development are creating favorable conditions for ELISA kit adoption. China, India, Japan, and South Korea represent important markets within the region.

South America and the Middle East and Africa are also expected to gradually expand as healthcare infrastructure and research capabilities improve.

Across regions, the increasing prevalence of growth disorders, demand for accurate diagnostic testing, and growing endocrinology research are supporting market development. Technological advances in assay sensitivity and detection methods are further improving the usefulness of IGF-1 ELISA kits.

Going forward, manufacturers can benefit from expanding distribution networks, developing high-sensitivity products, supporting personalized medicine research, and targeting emerging healthcare markets.